Revolution Medicines, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents
Revolution Medicines, Inc. (RVMD) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents of $860.92 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset › Business Combination, Recognized Asset Acquired, Asset, Current
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents · last filed 2026-02-25
- 2025-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $860.92M.
- 2024-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $860.92M.
- 2024-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $860.92M.
- 2024-06-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $860.92M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents |
|---|---|
| 2025-12-31 | $860.92M 10-K · filed 2026-02-25 |
| 2024-12-31 | $860.92M 10-K · filed 2025-02-26 |
| 2024-09-30 | $860.92M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $860.92M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $860.92M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $860.92M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |